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Abstract Inverted papillomas are a unique group of locally
aggressive benign epithelial neoplasms in the nasal cavity and
paranasal sinuses arising from the Schneiderian mucosa.
Metallothioneins are sulfhydryl-rich heavy metal-binding pro-
teins required for metal toxicity protection and regulation of
biological mechanisms including proliferation and invasion.
The goal of this study was to identify three SNPs at loci −5
A/G (rs28366003) and −209 A/G (rs1610216) in the core
promoter region and at locus +838 C/G (rs10636) in 3′UTR
region of the MT2A gene with IP risk and with tumor inva-
siveness according to Krouse staging. Genotyping was per-
formed using the PCR restriction fragment length polymor-
phism technique in 130 genetically unrelated IP individuals,
and 418 randomly selected healthy volunteers. The presence
of the rs28366003 SNP was significantly related to the risk of
IP within the present population-based case-control study.
Compared to homozygous common allele carriers, heterozy-
gosity and homozygosity for the G variant had a significantly
increased risk of IP (adjusted odds ratio [OR]=7.71, 95 %
confidence interval [CI]: 4.01–14.91, pdominant<0.001). More-
over, risk allele carriers demonstrated higher Krouse stage
(pT1 vs. pT2-4) (OR=19.32; 95 % CI, 2.30–173.53;
p<0.0001), diffuse tumor growth (OR=4.58; 95 % CI,
1.70–12.11; p=0.0008), bone destruction (OR=4.13; 95 %
CI, 1.50–11.60; p=0.003), and higher incidence of tumor re-
currences (OR=5.11; 95 % CI, 1.68–15.20; p=0.001). The
findings suggest that MT2A gene variation rs28366003 may
be implicated in the etiology of sinonasal inverted papilloma
in a Polish population.
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Introduction
Sinonasal inverted papillomas (Schneiderian papillomas) of
the nasal cavity and paranasal sinuses are unique, locally ag-
gressive, primarily benign epithelial neoplasms derived from
the Schneiderian membrane with an endophytic growth pat-
tern and proliferation in the underlying stroma. The character-
istic attributes of these head and neck tumors are local inva-
siveness and aggressive growth with local bone destruction
and a higher tendency to recur, resulting in appropriate clinical
problems. Moreover, once epithelial dysplasia in IP tissues
occurs, metaplasia and malignant transformation into carcino-
ma in situ or invasive squamous cell carcinomamay follow [1,
2]. Unfortunately, although a range of possible etiologies in-
cluding possible viral (HPV infection), inflammatory, envi-
ronmental, and occupational etiologies have been proposed,
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no conclusive basis has yet been identified for the develop-
ment and pathogenesis of Schneiderian papillomas [3, 4].
The metallothioneins (MTs) family of low molecular mass
(6–7 kDa) proteins is a family of metal-binding and metal-
absorbing, cysteine-rich molecules which affect the homeosta-
sis of intracellular metals such as cadmium, lead, mercury,
zinc, and copper [5–7]. MTs can react with heavy and trace
metal ions, thus regulating intra- and extracellular distribution
of the metal and its donation to various crucial transcription
factors and enzymes. Hence, MTs are involved in many path-
ophysiological processes including metal detoxification, cell
proliferation, apoptosis, and deactivation of reactive oxygen
species [5–8]. The transcription of the MT gene is activated in
response to a wide range of stimuli, including oxidative stress-
inducing agents, cytokines, hormones and various chemical
agents, as well as Cd and Zn in particular [5, 6, 9, 10]. A
crucial role in the activation of the metal-induced MT promot-
er region is played by the six zinc-finger-metal-responsive
transcription factor (MTF-1) and short cis-acting DNA metal
response elements (MREs) as transcriptional activators and a
nuclear factor I (NF-I) protein as a downregulator of MT ex-
pression [11]. MTF-1 also exerts effects on MT gene tran-
scription by independent increase in MTF-1 DNA-binding
activity [12, 13].
Eleven functional human MT isoforms have been identi-
fied so far. Among them, MT1/MT2 isoforms are the most
active in human cells and may participate as tumor regulators
in such crucial mechanisms as inhibition of NF-κB signaling,
modulation of p53 zinc-dependent activity, as well as regula-
tion of the PIK3/AKTand Rb/E2F pathways [9, 10, 14–17]. In
the last years, several association studies have been performed
which indicate that metallothioneins may be implicated in the
development of various types of human neoplastic diseases
and determine the clinical course of many tumors, e.g., larynx,
breast, kidney, lung, ovary, prostate, testis, urinary bladder,
cervical or pancreatic cancers [5, 9, 10, 14, 17–19]. Due to
the multidirectional nature of intracellular MT activity and
possible participation in such crucial tumorigenic processes
as differentiation, proliferation, angiogenesis and response to
oxidative stress species, many researchers examine its rela-
tionship as a potential biomarker with the etiology, progres-
sion and prognosis of various tumors, but with ambiguous and
often conflicting results [5–7, 9, 10, 14, 17, 18, 20].
Recently, an individual genetic variation identified in the
core promoter region of MTs and the diverse frequency of
essential MT alleles, in particular MT2A, was shown to be
associated with the risk of various human tumors in some
ethnic populations [5, 10, 18, 20–23]. The contribution of
single-nucleotide polymorphisms (SNPs) in the MT2A gene
to variation in the cellular activities of metallothioneins and
the signaling of MT-dependent pathways may steer the en-
hancement of tumor development and growth toward in-
creased DNA damage, enhanced genomic instability,
deregulated cell proliferation, inhibited apoptosis, and in-
duced oxidative stress [6, 8]. Thus, in the last half decade,
research has been focused on the identification of the after-
math and the mechanisms through which the presence of
SNPs in some genes, inter alia the MT2A gene, may induce
a malignant cell phenotype and determine cell proliferation,
growth and tumor invasion. However, such individual studies
concern only neoplasms of the head and neck region in such
locations as the nasopharynx, salivary glands, tongue, or lar-
ynx [10, 24–27]. Although the data indicates that the presence
of SNPs inMT genes has an impact onMT1/MT2 expression,
and that the occurrence of different genotypes are associated
with cancer risk, tumor behavior, and chemotherapy resistance
in head and neck cancers, these findings have not been unam-
biguously confirmed, and other studies suggest a range of
final conclusions [10, 24–27]. Despite conflicting data, most
research indicates that changes identified in the core promoter
region in the MT2A gene near the TATA box may be consid-
ered as novel biomarkers of risk and tumor invasiveness, as
well as a potential new therapeutic targets for treatment strat-
egies to modify or inhibit neoplastic development and pro-
gression of various types of tumors [5, 10, 18, 20–23].
Unfortunately, a literature survey reveals no publication
describing the activity of MT2A isoforms and their relation-
ship with the risk and tumor clinical behavior in sinonasal
Schneiderian papillomas. Moreover, the etiology of this dis-
ease is largely unknown, although epidemiological studies
suggest the involvement of viral, immunologic and occupa-
tional factors. Therefore, more research is needed to better
understand the possible biological mechanisms of develop-
ment and the potential role of both MT2A expression and
genetic polymorphism in theMT2A gene core promoter region
in this rare, locally aggressive tumorigenic process.
The present population-based case-control study was
aimed at investigating the genetic association between the risk
of sinonasal inverted papilloma (Schneiderian papilloma) in
inhabitants of Poland, and the presence of three selected
single-nucleotide polymorphisms: at loci −5 A/G
(rs28366003) and −209 A/G (rs1610216) in the core promoter
region and at locus +838 C/G (rs10636) in 3′UTR region of
theMT2A gene. In addition, the effect of these SNPs on allele-
specific gene expression and invasiveness of neoplastic pro-
cess according to Krouse staging and incidence of recurrences
has been identified.
Materials and methods
Study population and lifestyle risk factors
In this study, 130 tissue samples, including sinonasal inverted
papilloma (Schneiderian papilloma) cases from genetically
unrelated individuals (89 male and 41 female, mean age
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59.14±12.66 years), recruited between January 2003 and De-
cember 2014, were selected and investigated. The patients
were under treatment at the I and II Departments of Otolaryn-
gology and Laryngological Oncology, Medical University of
Łódź, Poland. All patients had received a confirmed diagnosis
of inverted papilloma (IP) based on histopathological evalua-
tion and had undergone functional endoscopic sinonasal sur-
gery (FESS), although this was dependent on the extent of
neoplastic lesions described by CT scans of nasal cavity and
paranasal sinuses performed before surgery and assessed dur-
ing an earlier FESS procedure. The observation period after
surgical treatment ranged from 5 to 154 months (mean period
59.37±37.63 months). Recurrence occurred after FESS in 18
(13.8 %) cases in the group studied. Sinonasal squamous cell
carcinoma (SCC) associated with IP (synchronous carcinoma)
was found in one case in group studied. The IP samples were
collected from the tumor localized in nasal cavities and/or
paranasal sinuses. The criteria for patient participation in this
study were as follows: (1) a pathologically confirmed diagno-
sis of sinonasal inverted papilloma (Schneiderian papilloma),
(2) a negative history of previously diagnosis with other types
of primary cancers, (3) a negative history of receiving prior
immuno-, radio- or chemotherapy due to other types of pri-
mary neoplasms. The control group comprised 418 randomly
selected healthy volunteers in the same age group (314 male
and 104 female, mean age 64.17±8.28 years) as previously
described [19]: all controls were non-related individuals who
had never been diagnosed with head and neck tumors nor any
other neoplasms, nor had they received prior immuno-, radio-
or chemotherapy for other reasons. All of the studied individ-
uals, patients and controls were Caucasians from the same
ethnic and geographical origins, living in the Łódź region of
central Poland. Informed consent was obtained from patients
and controls.
Socio-demographic data, health-related information and
cigarette smoking status were obtained from each participant.
In all cases, surveys were performed to complete the tumor
registry database. The database catalog was queried every
6 months and all histopathologically confirmed incidents of
sinonasal inverted papilloma cases reported within 6 months
of diagnosis preceding the recruitment were identified.
Smoking status was categorized into Bcurrent^, Bformer^,
and Bnever^ based on self-reported usage. Individuals who
reported smoking at least 100 cigarettes in their lifetime and
who, at the time of survey, smoked either every day or some
days were classified as a current smoker. Individuals who
reported smoking at least 100 cigarettes in their lifetime and
who had not been smoking for at least 3 months were defined
as a former smoker. Participants who reported never having
smoked 100 cigarettes were defined as a never smoker. A
positive family history of head and neck region neoplasms
was defined as being self-reported in at least one first-degree
relative with known neoplastic disease.
Histological classification and morphological features
All tissue samples were fixed in 10 % neutral buffered forma-
lin, embedded in paraffin, and routinely processed for histo-
logical examination. Archival paraffin-embedded tissue sam-
ples were used for the histological classification of tumors. At
this point in the study, all formalin-fixed, paraffin-embedded
(FFPE) slides were carried out in a single reference laboratory
and evaluated by two independent pathologists without prior
knowledge of patient clinical data. When differences in opin-
ion occurred between the two investigators, agreement was
reached by subsequent careful discussion. The inverted papil-
loma tissues used in this study in each case were selected
individually from several FFPE tissue sections which had
been estimated pathologically. H&E-stained sections provided
a histological confirmation of IP. Sinonasal inverted papillo-
mas were classified with the Krouse staging system [28]. The
IP were typed histopathologically according to the IARC
WHO classification of head and neck tumors [29]. Morpho-
logical estimation was performed on H&E-stained sections in
at least five different regions of the invasive, peripheral part of
the tumor (×200 magnification). The histological evaluation
considered the histological type (exophytic and endophytic
growth), the presence of dysplasia (mild or severe), bone de-
struction, anatomical area occupation and any association with
malignancy.
Immunohistochemistry
Paraffin-embedded tissue sections were mounted onto
SuperFrost slides, deparaffinized, then treated in a microwave
oven in a solution of target retrieval solution (TRS, pH 6.0,
Dako) for 30 min (2×6 min 360 W, 2×5180 W, 2×4 min
90 W) and transferred to distilled water. Endogenous peroxi-
dase activity was blocked by 0.3 % hydrogen peroxide in
distilled water for 30 min, and then sections were rinsed with
Tris-buffered saline (TBS, Dako, Denmark) and incubated
30 min with primary mouse monoclonal antibodies against:
Ki67 (Dako; clone MIB1, dilution 1:50). Immunoreactive
proteins were visualized using EnVision-HRP kit (Dako,
Carpinteria, CA, USA) according to the instructions of the
manufacturer. Visualization was performed by incubation the
sect ions in a solut ion of 3,3 ′ -d iaminobenzidine
(DakoCytomation, Denmark). After washing, the sections
were counter-stained with hematoxylin and coverslipped.
For each antibody and for each sample, negative controls were
processed. Negative controls were carried out by incubation in
the absence of the primary antibody and always yielded neg-
ative results. All immunohistochemical analyses were carried
out in a single reference laboratory and evaluated by light
microscopy blindly and independently by two pathologists.
Ki67 staining was performed routinely in all cases of dyspla-
sia and/or in those cases in which the histological evaluation
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of H&E-stained sections aroused any suspicion of increased
proliferation of tumor cells. Ki67 was scored as the percentage
of nuclei-stained cells out of all tumor cells in the front of the
neoplasm regardless of the intensity in ×400 high-power field,
500 to 1000 tumor cells were counted in each case. We clas-
sify IHC Ki67 expression into two categories according to the
score of Ki67: low (<14 % Ki67-positive cells) and high
(≥14 % Ki67-positive cells).
Sample collection and DNA and extraction from FFPE
The tissue specimens from sinonasal inverted papilloma col-
lected in the operation room were prepared and evaluated by
an experienced pathologist as mentioned above. Sections were
deparaffinized by two rinses in xylene and ethanol. After
deparaffinization, samples were rehydrated. The tissue was
collected by centrifugation. After the final wash, alcohol was
aspirated and the tissue pellets were resuspended in digestion
buffer (10 mM NaCl, 500 mM Tris-HCl, pH 8.0, 25 mM
EDTA, 1 % SDS) and 1 mg/ml proteinase K was added. Sec-
tions were incubated at 50 °C overnight. Prior to deoxyribo-
nucleic acid (DNA) purification, proteinase K was inactivated
by incubation at 97 °C for 10 min. The digested samples were
extracted using TRI Reagent (Sigma Aldrich Co., USA) ac-
cording to the manufacturer’s protocol. Venous blood samples
were obtained from each volunteer (10 ml) and transferred to
test tubes containing EDTA as an anticoagulant. After blood
collection, the tube was inverted 8–10 times and placed in a
refrigerator at −20 °C. Blood samples obtained from the partic-
ipants were stored at −20 °C within 2 h of removal. DNAwas
isolated by standard method using proteinase K digestion, phe-
nol chloroform extraction and ethanol precipitation. The inves-
tigations were performed with the approval of the Bioethical
Commission of theMedical University of Łódź and the Nation-
al Science Council, Poland (approval No RNN/60/13/KE).
Genotyping for the rs28366003, rs1610216, and
rs10636 allelic variants was performed as described previously
[18, 19].
Statistical data analysis
Genotype distributions were evaluated for agreement with
Hardy-Weinberg equilibrium by the Chi-square test (χ2). All
genotype distributions of MT2A fit the Hardy-Weinberg equi-
librium. Unconditional multiple logistic regression models
were used to calculate odds ratios (ORs) and 95 % confidence
intervals (CIs) for the association of genotype with inverted
papilloma risk. Genotype data was analyzed with the homo-
zygote of the common allele as the reference group. Variants
of homozygotes and heterozygotes were combined to evaluate
the dominant effect. For each SNP, trend tests were conducted
by assigning the values 1, 2, and 3 to homozygous wild type,
heterozygous, and homozygous variant genotypes,
respectively, and by adding these scores as a continuous var-
iable in logistic regression model.
The haplotype effects of the polymorphisms on inverted
papil loma risk were analyzed using Chaplin 1.2
(genetics.emory.edu) and THESIAS software (www.
genecanvas.org) . Al l haplotypes were examined
simultaneously in regression models with the most common
haplotype as the reference. Haplotypes were evaluated for
association with IP in unadjusted and adjusted logistic
regression models as for the individual SNPs. All
multivariate models were adjusted for age, gender, family
history, and smoking status. Reported p values were two
sided. Probabilities were considered significant whenever the
p value was lower than 0.05. All analyses were completed
using STATA software (version 11.0 Stata-Corp., Texas,
USA).
Results
The distribution of socio-demographic features of the study
subjects is shown in Table 1. All of the studied individuals,
patients and controls were Caucasians and constituted a ho-
mogenous population from the same ethnic and geographical
Table 1 Socio-demographic of inverted papilloma cases and controls
Cases n (%) Controls n (%) pa
Sample size n=130 n=418
Observation period, months 59.37±37.63 84.56±35.44
Age, years 59.14±12.66 64.17±8.28
<50 years 49 (37.7) 190 (54.5)
≥50 years 81 (62.3) 228 (45.5) 0.11
Gender
Male 89 (68.5) 314 (75.1) 0.13
Female 41 (31.5) 104 (24.9)
Family history of H&N tumors*
Yes 4 (3.1) 17 (4.1) 0.61
No 126 (96.1) 401 (95.9)
Smoking statusb
Smokers (current) 71 (54.6) 141 (33.7) <0.001
Non-smokers 59 (45.4) 277 (66.3)
Former 12 (9.2) 155 (37.1)
Never 47 (36.2) 122 (29.2)
a The chi-square (χ2 ) test
b Smoking was grouped into Bcurrent^, Bformer^ and Bnever^ based on
self-reported usage. Participants who reported smoking at least 100 cig-
arettes in their lifetime and who, at the time of survey, smoked either
every day or some days were defined as a current smoker. Participants
who reported smoking at least 100 cigarettes in their lifetime and who had
not been smoking for at least 3 months were defined as a former smoker.
Participants who reported never having smoked 100 cigarettes were de-
fined as a never smoker
H&N tumors benign or malignant tumors of head and neck region
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origins. On average, the cases with identified histopathologi-
cally sinonasal inverted Schneiderian papilloma (IP) were
slightly younger than controls (59.14 years±12.66 vs.
64.17 years±8.28 for controls) and more often qualified as
current smokers (54.6 vs. 33.7 % for controls). A positive
family history of benign or malignant head and neck region
tumors in at least one first-degree relative was mildly signifi-
cant compared to controls (3.1 vs. 4.1 % for controls). The
clinicopathological parameters of the inverted papillomas
studied are presented in Table 2. In the histological examina-
tion tumoric lesions in most cases were typed as endophytic
(91.5 %) according to the IARCWHO classification. IP cases
more likely to have diffuse tumor growth, as defined by a
simultaneous invasion of more anatomical sites (53.1 %) and
they appeared to dominate by pT2 (58.5 %) tumors according
to Krouse staging with maxillary or ethmoid anterior sinuses
occupation. Mild or severe dysplasia in tumor stroma and
invasive bone destruction were observed in 32.3 and 15.4 %
tumors, respectively. Typical histopathological features of the
inverted Schneiderian papilloma showing endophytic growth
of pseudostratified ciliated epithelium forming cystic




Variable Cases n (%)
Symptoms Nasal obstruction 64 (49.2)
Rhinorhoea 71 (54.6)
Feeling of pressure 24 (18.5)





Stage (Krouse classification)a pT1 40 (30.7)
pT2 76 (58.5)
pT3 13 (10.0)
pT4 (squamous cell carcinoma) 1 (0.8)
Histological typeb Endophytic growth 119 (91.5)
Exophytic growth 11 (8.5)
Cylindrical cell papilloma 0 (0.0)
Anatomical area occupiedc Nasal cavity 97 (74.6)
Maxillary sinuses 70 (53.8)
Ethmoid anterior sinuses 43 (33.1)
Ethmoid posterior sinuses 15 (11.5)
Frontal sinuses 8 (6.1)
Sphenoid sinuses 6 (4.6)
Anatomical sites occupied 1 region 61 (46.9)
More regions 69 (53.1)
IP with dysplasia (mild or severe) No 88 (67.7)
Yes 42 (32.3)
Ki67 IHC stainingd Low 5 (3.8)
High 46 (35.4)
Bone destruction No 110 (84.6)
Yes 20 (15.4)
Recurrences of IP No 112 (86.2)
Yes 18 (13.8)
IP associated with malignancy No 129 (99.2)
Yes 1 (0.8)
a Krouse staging system [28]
b The IARC WHO classification of head and neck tumors [29]
c In each IP case, one or more anatomical sites may be occupied simultaneously
d Low (<14 % Ki67-positive cells); high (≥14 % Ki67-positive cells)
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Fig. 1a–d. The locoregional recurrences were confirmed in
almost 14 % cases. Of the 51 cases (42 cases of dysplasia
and 9 IP cases in which the histological evaluation of H&E-
stained sections disclosed an increased proliferation of tumor
cells), 46 (35.4 %) tumors have high IHC Ki67 index, and
only 5 (3.8 %) cases were Ki67 low-stained. The representa-
tive images of low and high Ki67 immunoexpression in tis-
sues of inverted papilloma are shown in Fig. 2a, b.
Genotype and allele distributions in theMT2A gene in 130
genetically unrelated inverted papilloma patients and 418 con-
trols are summarized in Table 3. All genotype and allele fre-
quencies (−5 A/G, −209 A/G and +838 C/G) were confirmed
as compatible with Hardy-Weinberg equilibrium among the
cases and controls, respectively (all p>0.05). As a result, only
the −5 A/G (rs28366003) SNP in the MT2A gene was signif-
icantly related to Schneiderian papilloma in this population-
based case-control study. The frequency of A allele carriage
was 99.2 and 100 % in cases and controls, respectively. The G
allele carriage was detected in 24.6% of IP and in 4.1 % of the
non-IP samples. The respective genotype frequencies in the
promoter region at locus −5 (rs28366003) were found as ho-
mozygote typical (A/A), heterozygote (A/G) and homozygote
atypical (G/G) in 75.4, 23.8, and 0.8 % for cases, and 95.9,
4.1, and 0 % for controls. Likewise, genotype distribution
with regard to age, gender and smoking status was found to
be very similar. MT2A gene SNP in relation to age, gender,
and smoking status in cases and controls are shown in Table 4.
A significant interaction with gender for rs28366003 was ob-
served in cases (p=0.006). This suggests an influence of sex
on the association of MT2A gene SNP with IP. It should be
also emphasized that IP individuals with confirmed recur-
rences in follow-up in most cases appeared to have heterozy-
gosity (A/G) at locus −5 (rs28366003) (55.6 %). The
homozygote typical (A/A) constituted only 44.4 % of all these
cases. Mild or severe dysplasia was observed in 47.6 and
52.4 % carriers of the G and A allele, respectively. All cases
with low IHC Ki67 index were individuals with A/A geno-
type. Bone destruction was confirmed in 55 % of individuals
with one copy of the risk allele (G) at locus −5 (rs28366003)
MT2A and in 45 % of typical homozygotes. Malignant trans-
formation into squamous cell carcinoma also concerned indi-
viduals with an A/G genotype.
Our findings reinforce the association of MT2A
(rs28366003) with the risk of Schneiderian papilloma. In the
study population, the pathogenic link between the rs1610216
and rs10636 variants and this type of tumor was excluded. The
genetic association analysis revealed that the presence of A/G
allele atMT2A gene were at higher risk with an approximately
7.4-fold increase for the development of sinonasal inverted
papilloma (odds ratio [OR]=7.43; 95 % confidence interval
[CI], 3.91–14.46; p<0.001). Moreover, confirmation of one
copy of the risk allele (G) at locus −5 (rs28366003) of the core
promoter region of MT2A gene conferred an estimated in-
crease in Schneiderian papilloma of almost 7.7-fold in the
model adjusted for age, gender, family history and smoking
status (OR=7.71; 95 % CI, 4.01–14.91, pdominant<0.001). In-
dividuals with A/A genotype have a protective effect against
IP development. Four MT2A haplotypes were shown to have
a population frequency of at least 5 %. Interestingly, of the
four coding variants found solely in IP patients, a three-locus
haplotype (G-A-G) including the rs28366003 SNP variant
allele of the MT2A gene was found to be significantly associ-
ated with a 16 % increased risk of inverted papilloma (OR=
1.16; 95 % CI, 0.74–1.94, pglobal=0.02). The association be-
tween MT2A haplotypes and statistical analysis results of
Schneiderian papilloma risk are shown in Table 5.
Fig. 1 Inverted papilloma
without dysplasia (H&E, ×200
magnification) (a), inverted
papilloma without dysplasia and
prominent stromal edema (H&E,
×200 magnification) (b), inverted
papilloma with mild dysplasia
and signs of viral infection (H&E,
×200 magnification) (c), inverted
papilloma with severe dysplasia
(H&E, ×200 magnification) (d)
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Since a significant association was confirmed between −5
A/G SNP and the risk of inverted papilloma, it was investi-
gated whether genetic variation identified in the core promoter
region can affect tumor behavior, as defined bymorphological
evaluation. The SNP at locus −5 (rs28366003) was also found
to be associated with IP phenotype in a Polish population. The
heterozygotes of the major allele and atypical homozygotes
appeared to have higher Krouse stage (pT1 vs. pT2–4) (OR=
19.32; 95 % CI, 2.30–173.53; p<0.0001), more diffuse tumor
growth, as defined by a simultaneous occupation of more
anatomical sites (OR=4.58; 95 % CI, 1.70–12.11; p=
0.0008) and bone destruction (OR=4.13; 95 % CI, 1.50–
11.60; p=0.003). A similar significant association was deter-
mined for the risk allele carriage with regard to higher inci-
dence of tumor recurrences in follow-up (OR=5.11; 95 % CI,
1.68–15.20; p=0.001). Confirmation of one copy of the risk
allele (G) in the core promoter region ofMT2A gene conferred
an estimated five-fold increase in local relapse of neoplastic
process. The associations between clinicopathological charac-
teristics and papilloma inverted risk are shown in Table 6.
Discussion
The present work evaluates the effect of genetic polymor-
phisms in the MT2A core promoter region on the risk and
tumor behavior of sinonasal Schneiderian papilloma in a Pol-
ish population. It should be emphasized that, at the time of
writing, no publication has yet analyzed the SNPs ofMT2A in
relation to human inverted papilloma susceptibility. Moreover,
this is also the first study to investigate the expression of
MT2A isoforms in IP biopsy tissue and to document the rela-
tionship between MT2A SNPs and aggressive phenotype of
this type of head and neck tumor. Therefore, our findings may
only be compared with those of studies carried out for other
types of head and neck cancers or human neoplasms in other
localizations. It should also be noted that, to our knowledge,
the material studied constitutes the largest homogeneous
group of these benign, locally aggressive head and neck tu-
mors which share both the same tissue origin and histological
type according to the IARC WHO classification. This is an
additional value of this research, when the difficulties in
obtaining such rare pathological material collected over many
years are taken into consideration. Because of these con-
straints, an overwhelming proportion of inverted papilloma
research has used only paraffin-embedded archival material,
often histologically heterogenous and thus limited in number,
with fewer than fifty cases being included in most studies. The
limitations described doubtlessly have an impact on the final
results and the data interpretation in terms of the mechanisms
of the tumorigenesis of this neoplastic lesion. Hence, greater
knowledge of the SNPs of MT2A and their relationship with
human inverted papilloma tumorigenesis and behavior is
needed to e lucidate the biologica l funct ions of
metallothioneins in this neoplastic process, and to determine
their possible clinical significance as biomarker of the dynam-
ics of tumor growth, invasiveness, and prognosis. Three ana-
lyzed SNPs that could potentially affect MT2A gene expres-
sion were selected on the basis of a literature review.
In recent years, the possible role of various metallothionein
isoforms and polymorphisms on physiological and patholog-
ical processes has been documented [6, 10, 30]. Since the
expression of MTs can be affected by genetic variation in
the core promoter region and diverse frequency of the essen-
tial alleles, the presence of SNPs may lead to reduced cellular
activity of metallothioneins and affect abnormal intracellular
pathways of cell proliferation, apoptosis, and response to ox-
idative stress, thus potentially influencing the susceptibility of
the individual to various types of tumors [6, 8, 20–22, 31–33].
Unfortunately, among the several previous reports on the
rs28366003, rs1610216, and rs10636 SNPs in the MT2A
gene, only single studies related to the neoplastic process re-
port the frequency of MT isoforms within different ethnic
populations [20–23, 34–38].
Our study documents for the first time the genetic associa-
tion between the occurrence of −5 A/G SNP in the core pro-
moter region of the MT2A gene and the risk of sinonasal
inverted papilloma, as well as the dynamics of tumor growth
according to Krouse staging, a precise, multifactorial
Fig. 2 Ki67 immunohistochemistry (IHC): the low immunoexpression
of Ki67 in inverted papilloma without dysplasia (×100magnification) (a),
the high immunoexpression of Ki67 in inverted papilloma with severe
dysplasia (×100 magnification) (b)
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Table 4 MT2A gene −5 A/G
rs28366003 polymorphism in
relation to age, gender and
smoking status in an inverted
papilloma (cases) and non-
papilloma cases (controls)
Variable Genotype n (%) pa
A/A A/G G/G
IP—cases
Age <50 years (n=49) 40 (30.8) 8 (6.1) 1 (0.8) 0.42
≥50 years (n=81) 58 (44.6) 23 (17.7) 0 (0.0)
<50 years (years±SD) 47.9±15.8 46.8±12.34 47 -
≥50 years (years±SD) 62.1±13.9 52.0±16.5 -
Gender Male (n=89) 59 (45.4) 29 (22.3) 1 (0.8) 0.006
Female (n=41) 39 (30.0) 2 (1.5) 0 (0.0)
Smoking status Smokers (n=71) 51 (39.2) 19 (14.6) 1 (0.9) 0.77
Non-smokers (n=59) 47 (36.1) 12 (9.2) 0 (0.0)
non-IP—controls
Age <50 years (n=190) 185 (44.2) 5 (1.2) 0 (0.0) 0.17
≥50 years (n=228) 216 (51.7) 12 (2.9) 0 (0.0)
<50 years (years±SD) 53.1±14.6 46.2±11.4 – –
≥50 years (years±SD) 67.3±12.5 51.1±12.1 –
Gender Male (n=314) 305 (73.0) 9 (2.1) 0 (0.0) 0.03
Female (n=104) 96 (23.0) 8 (1.9) 0 (0.0)
Smoking status Smokers (n=141) 128 (30.6) 13 (3.1) 0 (0.0) 0.0001
Non-smokers (n=277) 273 (65.3) 4 (1.0) 0 (0.0)
a The chi-square (χ2) test
Table 3 Associations between MT2A SNPs and inverted papilloma risk
SNP genotype Cases (%)/controls (%) OR (95 % CI)a p OR (95 % CI)b p
rs28366003
AA 98 (75.4)/401 (95.9) 1.00 (reference) 1.00 (reference)
AG 31 (23.8)/17 (4.1) 7.46 (3.84–14.47) <0.001 7.43 (3.91–14.46) <0.001
GG 1 (0.8)/0 (0.0) –
p trendc <0.0001
AG or GG vs. AAd 32 (24.6)/17 (4.1) 7.70 (3.97–14.91) <0.001 7.71 (4.01–14.91) <0.001
AG or AA vs. GGe 129 (99.2)/418 (100.0) – –
rs1610216
AA 96 (73.8)/309 (73.9) 1.00 (reference) 1.00 (reference)
AG 33 (25.4)/106 (25.3) 1.00 (0.64–1.58) 0.99 1.01 (0.66–1.58) 0.99
GG 1 (0.8)/3 (0.8) 1.07 (0.11–10.46) 0.95 1.07 (0.10–10.44) 0.94
p trendc 0.97
AG or GG vs. AAd 34 (26.1)/109 (26.1) 1.00 (0.64–1.57) 0.99 0.99 (0.61–1.56) 0.99
AG or AA vs. GGe 129 (99.2)/415 (99.3) 1.07 (0.11–10.42) 0.95 1.07 (0.13–10.42) 0.95
rs10636
GG 58 (44.6)/213 (50.9) 1.00 (reference) 1.00 (reference)
GC 56 (43.1)/172 (41.2) 1.19 (0.78–1.82) 0.40 1.23 (0.72–1.82) 0.40
CC 16 (12.3)/33 (7.90) 1.78 (0.91–3.47) 0.09 1.78 (0.94–3.47) 0.09
p trendc 0.1
GC or CC vs. GGd 72 (55.4)/205 (49.0) 1.29 (0.87–1.92) 0.21 1.30 (0.87–1.95) 0.22
GC or GG vs. CCe 114 (87.7)/385 (92.1) 1.64 (0.87–3.09) 0.12 1.65 (0.83–3.10) 0.13
a Crude
bAdjusted for age, gender, family history and smoking status
c Testing additive genetic model (Cochran-Armitage test for trend)
d Testing dominant genetic model
e Testing recessive genetic model
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histological analysis of biopsy material and incidence of re-
currences. The harvested data indicates that a positive rela-
tionship exists between (rs28366003) SNP and both higher
susceptibility and increased invasiveness of Schneiderian pap-
illoma in Polish inhabitants.
As a result, the genotype frequencies in the core promoter
region at locus −5 A/G (rs28366003) were found to be homo-
zygote typical (A/A) in 75.4 %, heterozygote (A/G) in 23.8 %
and homozygote atypical (G/G) in 0.8 % individuals with
sinonasal inverted papilloma. Our recent study has also report-
ed a similar prevalence of A by G replacement at position −5
in the core region of the MT2A promoter for homozygous
common allele carriers as well as for heterozygosity and ho-
mozygosity for the G variant in the studied IP group [39]. The
resulting data resemble the findings in some ethnic popula-
tions such as those from Japan, Turkey, and America [23,
36–38]. For example, Kita et al. [23] report that an incidence
of the conversion A→G in the core promoter region of the
MT2A gene near the TATA box was 18% for Japanese people,
with the carriage of different genotypes being 82, 17, and
0.9 % for A/A, A/G, and G/G, respectively. Similar results
were detected by Kayaalti and Söylemezoğlu [37] within a
Turkish population, wherein the genotype frequencies of −5
A/G SNP were observed as homozygote typical in 87 %,
heterozygote in 12.3 %, and homozygote atypical in 0.7 %
individuals. In another study, the same researchers observe a
high dependence of MT2A core promoter gene polymor-
phisms with aging and conclude that absence of a risk allele
variant (G) may be associated with better survival [36]. Sim-
ilarly, McElroy et al. [38] demonstrated the allele G was not
frequent genetic variation at rs28366003 in MT2A gene in
black and white female volunteers in the Midwestern United
States. In this population, the prevalence of the minor allele
was found to be 6.4 % for white and 1.1 % for black
individuals.
The data concerning MT2A genotype frequencies identi-
fied in the different neoplastic processes were also found to be
very similar to our results: the most frequent genotype was
A/A, while heterozygosity and homozygosity for the risk G
variant was less so [20–22]. The genotype distributions of
MT2A (rs28366003) SNP in prostate cancer and breast cancer
described byKrześlak et al. [20, 21] confirm those given in the
present study and were found to be A/A in 76 %, A/G in
21.1 %, G/G in 2.9 % and A/A in 87.1 %, A/G in 12.3 %,
G/G in 0.6 % in prostate and breast cancer cases, respectively.
The present study documents the contribution of the −5
A/G single-nucleotide polymorphism in the MT2A gene to-
ward the risk of developing inverted papilloma in a Polish
Table 5 Associations between
MT2A haplotypes and inverted
papilloma risk
Haplotypes (SNP1–SNP3) Cases (%)/controls (%) OR (95 % CI)a OR (95 % CI)b
A-A-G 53 (40.8)/133 (31.8) 1.00 (reference) 1.00 (reference)
G-A-G 41 (31.5)/87 (20.8) 1.18 (0.72–1.93) 1.16 (0.74–1.94)
A-A-C 21 (16.1)/104 (24.9) 0.51 (0.28–0.89) 0.49 (0.27–0.89)
A-G-C 15 (11.6)/94 (22.5) 0.40 (0.21–0.76) 0.40 (0.24–0.75)
a Crude
bAdjusted for age, gender, family history, and smoking status
Table 6 Associations between clinicopathological characteristics and papilloma inverted risk
Variable SNP rs28366003 OR (95 % CI)a p OR (95 % CI)b p
AA n (%) AG or GG n (%)
Stage (Krouse system) pT1 vs. pT2–T4 39 (30.0)/59 (45.4) 1 (0.8)/31 (23.8) 20.49 (2.34–179.64) <0.0001 19.32 (2.30–173.53) <0.0001
Histological type exo vs. endophytic 11 (8.5)/87 (66.9) 2 (1.5)/30 (23.1) 1.89 (0.39–9.14) 0.41 1.87 (0.40–9.14) 0.42
Anatomical areac NS/M/EA vs. EP/F/S 81 (62.3)/17 (13.1) 22 (16.9)/10 (7.7) 2.16 (0.86–5.47) 0.09 2.15 (0.86–5.39) 0.08
Anatomical sites 1 region vs. more 55 (42.3)/43 (33.1) 7 (5.4)/25 (19.2) 4.57 (1.72–12.11) 0.0008 4.58 (1.70–12.11) 0.0008
Dysplasia no vs. yes (mild/severe) 76 (58.5)/22 (16.9) 12 (9.2)/20 (15.4) 2.13 (0.92–4.90) 0.07 2.14 (0.97–4.91) 0.07
Bone destruction no vs. yes 85 (65.4)/9 (6.9) 25 (19.2)/11 (8.5) 4.15 (1.49–11.60) 0.003 4.13 (1.50–11.60) 0.003
Recurrences no vs. yes 90 (69.2)/8 (6.2) 22 (16.9)/10 (7.7) 5.11 (1.71–15.21) 0.001 5.11 (1.68–15.20) 0.001
a Crude, AA vs. AG or GG MT2A SNP rs28366003 (the homozygote of the common allele were estimated as the reference group)
b Adjusted for age, gender, family history and smoking status
c In NS/M/EA cases only nasal cavity, maxillary sinuses and/or ethmoid anterior sinuses were occupied; In EP/F/S cases besides nasal cavity, maxillary
sinuses and/or ethmoid anterior sinuses the other anatomical sites such as ethmoid posterior sinuses, frontal sinuses and/or sphenoid sinuses were
occupied simultaneously (NC nasal cavity,Mmaxillary sinuses, EA ethmoid anterior sinuses, EP ethmoid posterior sinuses, F frontal sinuses, S sphenoid
sinuses)
Tumor Biol. (2015) 36:8559–8571 8567
population. It was also determined that confirmation of one
copy of the risk allele (G) at locus −5 (rs28366003) of the core
promoter region ofMT2A gene conferred 7.7-fold increase in
Schneiderian papilloma risk in a model adjusted for age, gen-
der, family history, and smoking status.
Unfortunately, as a literature survey revealed no publica-
tion describing a genetic implication of MT2A SNPs in the
pathogenesis of head and neck tumors, the harvested results
can only be compared to our previous reports in laryngeal
cancer [18, 19]. The results indicate that the presence of an
SNP in the core promoter region at locus −5 A/G
(rs28366003) in the MT2A gene contributes to a higher risk
of malignant head and neck tumors.
It should be also added that only a few studies found in the
literature concern metallothionein genetic variations in rela-
tion to pathological mechanisms, as well as to the develop-
ment, tumor behavior, and progression of other neoplastic
lesions [20–22, 31–33]. The studies indicate that MT2A core
promoter region genetic polymorphism and in particular con-
firmation although of one copy of the risk allele at rs28366003
in the MT2A gene may have an impact on cancer risk of
various origins. In this context, our findings for sinonasal
inverted papilloma resemble the findings in other cancers.
AberrantMTexpression due to altered transcription at the core
promoter region of the MT2A gene, as a reason of enhanced
sensitivity for the carcinogenic heavy metals and metallic
agents and deregulation of cell proliferation and inhibition of
apoptosis, have been discussed [5, 20–22, 32, 33]. For exam-
ple, Forma et al. [22] demonstrated almost 1.3- and 4.3-fold
greater risks of primary prostate cancer associatedwith SNP in
MT2A (rs28366003) linked to heterozygosity and homozy-
gosity for the risk G allele, respectively, in the model adjusted
for age. A similar result was reported by Krześlak et al. [21]
for the same type of cancer in which a 2.6-fold increase in risk
in heterozygous G allele carriers compared to individuals who
were homozygous for allele A was established. Moreover, it
was demonstrated that enhanced susceptibility to neoplasm
was related to aberrant expression of MT2A and Cd, Zn, Cu,
and Pb content in biopsy neoplastic tissue. In another study,
the same researchers also observed an increase of almost 90%
in the risk of ductal breast cancer after adjustment for inter alia
age, family history, smoking status, menarche and menopaus-
al status in subjects having one copy of the risk G allele in
MT2A promoter region as well as an increase of 50 % in risk
of cancer when MT2A haplotypes G-A-G was taken into ac-
count. An association between otherMT2A SNPs and suscep-
tibility to tumorigenesis was also detected, confirming several
previous reports. For instance, Seibold et al. [32, 33] docu-
mented a significant modification of post-menopausal breast
cancer risk per specific alleles of six polymorphisms, includ-
ing SNP in MT2A (rs1580833) and its association with the
overall mortality of the subjects. Regardless of different types
of cancers discussed in the literature, the findings are in line
with other research suggesting potential role of MT2A SNP in
determining the risk of neoplastic process.
Since the conversion of nucleotides A to G in the core
promoter region ofMT2A gene may affect the MT gene tran-
scription induced by heavy metals and metallic agents and
consequently lead to higher sensitivity to metal toxicity, the
risk of tumors of various origin due to SNP has been evaluated
in certain tumors [5, 20–23]. The direct functional connections
and an understanding of the specific mechanisms through
which the SNP in the MT2A gene regulate toxic metal con-
centrations as potential carcinogenic factors and influence tu-
mor cell dynamics and pathology have been reported in only a
few publications and remain elusive [5, 8, 20, 33–35, 40–42].
The study by Kayaalti et al. [34] provides evidence implicat-
ing MT2A SNP polymorphisms on heavy metal expression in
the blood samples taken from a Turkish population. A confir-
mation of homozygosity for the risk allele variant (G) at locus
−5 (rs28366003) inMT2A gene determined higher Cd and Pb
concentration compared with A/A and A/G genotypes, as well
as higher sensitivity for heavy metal toxicity. However, in
contrast to the present study, the same authors report that cer-
tain genetic variations such as heterozygosity and atypical
homozygosity influence higher accumulation of Cd in autopsy
kidney tissues, but no association was found between −5 A/G
SNP and both Zn and Cu levels in the renal cortex [35]. Also,
Tekin et al. [43] observed the implication of A/G genotype
carriage in the MT2A promoter region on the increased Pb
concentration in blood samples and placental tissue in preg-
nant women and the risk of low-level cord blood lead varia-
tion in their newborns. The harvested data resemble our recent
findings in inverted papilloma, in which a significant connec-
tion was observed between rs28366003 and a considerably
high accumulation of both Cd and Cu in biopsy tissue [39].
These changes in toxic metal levels in neoplastic tissue remain
in line with our previous studies on laryngeal cancer, which
note that −5 A/G SNP in theMT2A gene may be related to Cd,
Zn, and Cu content [18].
Our study also documents the relationship between the
SNPs in the MT2A gene and the dynamics of tumor growth,
according to a thorough multifactorial histological evaluation
of inverted papillomas. The current data confirms that the
carriage of the risk allele (G) was associated with increased
tumor invasiveness according to Krouse grading, and a higher
incidence of recurrences when compared with typical homo-
zygous patients. This data is also confirmed by our previous
study of laryngeal cancers, which notes that −5 (rs28366003)
of the core promoter region ofMT2A gene was found to exert
issue impact on malignant tumor behavior [19].
Unfortunately, a literature search indicates that no studies
have yet been performed on the relationship between SNPs at
rs28366003 MT2A and phenotype of aggressiveness in tu-
mors of the head and neck region. However, some studies
have linked MT isoform function to neoplastic cell dynamics
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and tumor pathology in other neoplasms, yet findings remain
limited and often divergent, especially regarding the impact of
their specific isoforms on tumor invasion and prediction of
patient outcome [5, 10, 20–23]. Most researchers have con-
firmed increased expression of MT1 and MT2 and a positive
association of these isoforms with standard clinical parameters
such as higher pTNM classification, higher stage, lower his-
tological differentiation as well as chemotherapy and radiation
resistance and shorter survival time. However, MTexpression
does not affect the clinical disease parameters and mortality in
other types of tumors, i.e., hepatocellular, gastric, colorectal,
central nervous system, and thyroid cancers [10, 25, 44].
Nevertheless, contrary results for MT expression related to
tumor behavior, chemo-, and radiotherapy response and prog-
nosis in head and neck neoplasms have also been reported in a
few available studies [10, 26, 27, 45]. For instance, Pedersen
et al. [10] report increased expression of MT1 and MT2 iso-
forms in human head and neck primary cancers of the naso-
pharynx, salivary gland, thyroid, and larynx. Also, Theocharis
et al. [26] determined the impact of MTcellular distribution in
either the tumor itself, or adjacent epithelial mucosa tissue on
the development and progression of mobile tongue cancer.
The authors note that the occurrence of positive MT expres-
sion is frequently characteristic of tumors with lower histolog-
ical grade, vascular invasion, deep infiltration, and the exis-
tence of lymph nodemetastases. Similarly, Gumulec et al. [14]
estimate a positive association of MT immunoexpression with
advanced tumor grade and shorter patient survival in head and
neck malignant tumors. By contrast, other researchers have
not confirmed that MT expression corresponds to
clinicomorphological parameters in tumors of the head and
neck region [27, 45]. For example, Pastuszewski et al. [27]
document the opposite findings in laryngeal carcinomas. In
this case, MT expression was found to be not significantly
related to the tumor grade, stage or clinical outcome parame-
ters. The results described by Dutsch-Wicherek et al. [45]
were almost the same as those given in the mentioned study.
MTstaining in tumor infiltration was lower than in peri-tumor
stroma tissue and has been found not to be associated with
nodal metastases in head and neck cancer and breast adeno-
carcinoma population. The researchers suggest that MT ex-
pression may be due to a protective reaction of healthy non-
cancerous tissue to the tumor antigens.
In addition, a literature review reveals a wide range of
findings concerning MT expression also identified in other
types of neoplastic lesion. Most of the data indicate that
MT2A transcripts or, most often, protein expression in tumors
may be involved in determining aggressive tumor behavior
and increased patient mortality, however, many demonstrate
equivocal results and divergent conclusions [16, 17, 25, 44,
46–48]. For example, Werynska et al. [48] report enhanced
MT2A isoform expression in a studied population of non-
small cell lung cancer cases, and identify a positive
association between MT immunostaining and primary tumor
size, grade of malignancy and poor prognosis. Similarly,
Kobierzycki et al. [46] observe MT1/MT2 cytoplasmic over-
expression in neoplastic tissues in ovarian cancer and con-
clude these proteins can be predictive markers for advanced
stage. Also, Habel et al. [16] indicate that higher MT2A level
may also correspond to lower mortality rate and has an effect
on chemoresistance to cytotoxic drugs in patients treated with
osteosarcoma. A similar result was reported by Gumulec et al.
[25] for prostate cancer model. In this study, upregulation of
MT2A at the protein level was established to be involved in
CDDP resistance. However, Gansukh et al. [44] demonstrate
no significant correlation between MTexpression and cisplat-
in sensitivity in non-small cellular lung cancer. Liang et al.
[47] also suggest that the downregulation of MT2A gene lev-
el, rather than increasedMTexpression, may play the key role
in lung carcinogenesis. Similarly, Pan et al. [17] suggest that
MT2A exerts tumor suppressive activity and observe that de-
creased MT2A expression in cell lines and primary tumors
correlates with advanced clinical stage and poor prognosis in
gastric cancer.
It should be also emphasized that there are several limita-
tions of our study and constraints in interpreting results
concerning the metallothionein 2A activity and MT2A SNPs
in tumorigenesis and neoplastic progression. While the −5
(rs28366003) SNP in the MT2A gene could be considered as
a potential biomarker for the etiopathology and a higher sus-
ceptibility of sinonasal inverted papilloma, as well as an indi-
cator of the dynamics of tumor growth, discrepancies shown
in the discussion exist for other neoplastic lesions due to var-
iation of tumor origins, proliferation, and histological differ-
entiation status, which cause differences in their biology. It
should be also stressed that the difficulties in obtaining human
autopsy materials and using cell culture or laboratory animal
material, as well as the diversity of tissues used (fresh tumor
samples, cell lines, or blood), may affect the final results of
research.Moreover, the relatively small size and heterogeneity
of groups studied, the small proportion of homozygote atypi-
cal, and variety of analyzed populations can influence the
resulting odds ratio estimates and may cause difficulties in
the interpretation of results.
Our study provides evidence for implicating MT2A poly-
morphisms in the development of sinonasal inverted papillo-
ma. The findings also illustrate the key role played by the
rs28366003 SNP in theMT2A gene in inducing an aggressive
Schneiderian papilloma phenotype. These observations pro-
vide future possible targets for diagnosis and novel therapeutic
strategies for inhibition of tumorigenesis, growth, and pro-
gression of this locally aggressive process. However, we real-
ize that our findings represent only one voice in an ongoing
discussion and further studies of greater dimensions are re-
quired to determine the precise role of MT2A in the carcino-
genicity and physiopathology of neoplastic diseases.
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Conclusions
In conclusion, despite the limitation discussed, accumulating
evidence indicates that the genetic variation of MT2A may
contribute to the pathogenesis of sinonasal Schneiderian
inverted papilloma in a Polish population. The identification
of these tumor-related −5 A/G (rs28366003)MT2A gene poly-
morphisms could also be concerned with the more aggressive
local behavior of inverted papilloma cases and used as a po-
tential prognostic biomarker
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